ESTABLISHED HUMAN GENETICS
Reduced functional dosage can cause disease.
This establishes the gene–disorder relationship. It does not rank organs or predict the effect of every molecular finding.
TISSUE BIOLOGY · RESEARCH AGENDA
Move from tissue plausibility to patient-variant mechanism.
The next step is not more organ-name association. It is paired human phenotyping and allele-aware measurement in the cell states capable of answering the question.
COMPLETE EVIDENCE LADDER
Expression, experiments, and human evidence answer different questions.
A supported mechanism would need to connect gene dosage, the relevant human cell state, a direct experiment, measurement of a patient allele, and rescue of the measured effect.
NORMAL HUMAN EXPRESSION
ASH1L RNA is broadly detected.
Normal reference atlases identify candidate tissues and cell classes. They do not measure altered dosage, protein function, or the effects of ASH1L-related changes in people.
DIRECT PERTURBATION
Function depends on cell identity and state.
Neural, immune, epidermal, muscle, bone, hematopoietic, reproductive, and cardiac models answer defined questions within their tested species and perturbation.
UNRESOLVED HUMAN MECHANISM
Which patient allele changes which function?
Link residual dosage to a matched cell state, time course, functional readout, isogenic control, and rescue before assigning a tissue mechanism.
DIRECT MODEL RESULT
The 2026 neural CRISPR study showed cell-state-dependent consequences across modeled neural progenitors and neuronal identities.
WHAT THIS DOES NOT ESTABLISH
Complete engineered knockout is not a patient-allele dosage series and does not establish a person-level tissue mechanism.
HUMAN RESEARCH AGENDA
6 allele-aware priorities.
Each priority pairs the human question with the cell state, comparison, time course, or rescue needed to test it.
Brain, glia & memory
Measure allele-specific RNA/protein dosage in neurons and glia across differentiation; separate encoding, stabilization, retrieval, sleep state, and network excitability in human phenotyping.
Oral, enteric & GI
Build oral epithelial, enteric-neuron, smooth-muscle, and intestinal models only alongside objective feeding, motility, growth, or mucosal phenotypes.
Immune, skin & barrier
Pair defined clinical events with immune-cell, epithelial, and recovery assays. Systemic ESR/CRP and tissue-local function are different measurements.
Muscle & bone
Use standardized strength, fatigue, gait, fracture, mineral, and DXA phenotyping where indicated; then connect selected alleles to myoblast and osteoclast assays.
Endocrine & reproductive
Capture puberty, cycle, growth, and endocrine trajectories prospectively before selecting hormone-responsive cell models. Expression alone is not treatment evidence.
Cardiac, autonomic & renal
Start with reproducible human physiology—ECG, vitals, imaging, laboratory, or functional anchors—before assigning tissue-autonomous ASH1L mechanism.